Ignite Creation Date:
2024-05-06 @ 3:54 PM
Last Modification Date:
2024-10-26 @ 2:00 PM
Study NCT ID:
NCT04806594
Status:
COMPLETED
Last Update Posted:
2022-01-21
First Post:
2020-11-13
Brief Title:
Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar
Sponsor:
Relife Srl
Organization:
Relife Srl
Study Overview
Official Title:
Open Label Uncontrolled Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar in the Prevention and Improvement of Scars and Lesions Associated With Acne
Status:
COMPLETED
Status Verified Date:
2022-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne The product will be applied for 8 consecutive weeks and 3 clinical follow up visits will be performed
Detailed Description:
The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne The product will be applied for 8 consecutive weeks 2 times per day into the face
The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product
The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None